Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)
Saudi Arabia
· Delayed Price · Currency is SAR 153.20
-3.60 (-2.30%)
Apr 17, 2025, 3:19 PM AST
TADAWUL:4015 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 1,318 | 1,101 | 916.67 | 735.68 | 805.31 | Upgrade
|
| Revenue Growth (YoY) | 19.77% | 20.09% | 24.60% | -8.65% | 10.06% | Upgrade
|
| Cost of Revenue | 500.31 | 399.03 | 325.19 | 260.99 | 328.51 | Upgrade
|
| Gross Profit | 818.17 | 701.79 | 591.49 | 474.69 | 476.81 | Upgrade
|
| Selling, General & Admin | 385.36 | 350.42 | 314 | 251.89 | 236.89 | Upgrade
|
| Research & Development | 34 | 33.39 | 32.68 | 37 | - | Upgrade
|
| Other Operating Expenses | -0.39 | 0.08 | - | - | - | Upgrade
|
| Operating Expenses | 430.35 | 385.98 | 349.03 | 288.89 | 236.89 | Upgrade
|
| Operating Income | 387.82 | 315.8 | 242.46 | 185.8 | 239.91 | Upgrade
|
| Interest Expense | -0.1 | -0.11 | -0.12 | - | - | Upgrade
|
| Interest & Investment Income | 6.94 | - | - | - | 1.5 | Upgrade
|
| Earnings From Equity Investments | 18.57 | 4.41 | -0.32 | -0.05 | -0.57 | Upgrade
|
| Currency Exchange Gain (Loss) | -18.75 | -1.33 | -47.95 | 2.01 | 4.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -7.3 | -3.02 | -6.54 | 1.28 | -2.88 | Upgrade
|
| EBT Excluding Unusual Items | 387.18 | 315.76 | 187.53 | 189.04 | 242.08 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.52 | 0.04 | 0.01 | -1.04 | -8.32 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.03 | 0.09 | 0.09 | Upgrade
|
| Asset Writedown | - | - | -1.25 | - | - | Upgrade
|
| Pretax Income | 382.65 | 315.8 | 186.31 | 188.09 | 231.74 | Upgrade
|
| Income Tax Expense | 26.13 | 23.4 | 15 | 17.39 | 24.88 | Upgrade
|
| Earnings From Continuing Operations | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 | Upgrade
|
| Net Income | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 | Upgrade
|
| Net Income to Common | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 | Upgrade
|
| Net Income Growth | 21.93% | 70.68% | 0.36% | -17.48% | 31.82% | Upgrade
|
| Shares Outstanding (Basic) | 70 | 70 | 70 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 70 | 70 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | - | - | 600.00% | - | - | Upgrade
|
| EPS (Basic) | 5.09 | 4.18 | 2.45 | 17.07 | 20.69 | Upgrade
|
| EPS (Diluted) | 5.09 | 4.18 | 2.45 | 17.07 | 20.69 | Upgrade
|
| EPS Growth | 21.93% | 70.68% | -85.66% | -17.48% | 31.82% | Upgrade
|
| Free Cash Flow | 206.47 | 250.74 | 143.2 | 101.9 | 113.41 | Upgrade
|
| Free Cash Flow Per Share | 2.95 | 3.58 | 2.05 | 10.19 | 11.34 | Upgrade
|
| Dividend Per Share | 3.060 | 2.500 | - | - | - | Upgrade
|
| Dividend Growth | 22.40% | - | - | - | - | Upgrade
|
| Gross Margin | 62.05% | 63.75% | 64.53% | 64.52% | 59.21% | Upgrade
|
| Operating Margin | 29.41% | 28.69% | 26.45% | 25.26% | 29.79% | Upgrade
|
| Profit Margin | 27.04% | 26.56% | 18.69% | 23.20% | 25.69% | Upgrade
|
| Free Cash Flow Margin | 15.66% | 22.78% | 15.62% | 13.85% | 14.08% | Upgrade
|
| EBITDA | 424.44 | 341.7 | 266.57 | 209.63 | 281.88 | Upgrade
|
| EBITDA Margin | 32.19% | 31.04% | 29.08% | 28.49% | 35.00% | Upgrade
|
| D&A For EBITDA | 36.62 | 25.89 | 24.12 | 23.82 | 41.96 | Upgrade
|
| EBIT | 387.82 | 315.8 | 242.46 | 185.8 | 239.91 | Upgrade
|
| EBIT Margin | 29.41% | 28.69% | 26.45% | 25.26% | 29.79% | Upgrade
|
| Effective Tax Rate | 6.83% | 7.41% | 8.05% | 9.25% | 10.74% | Upgrade
|
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.